Surveillance Options for Individuals with BRCA1 or BRCA2 Mutations

	Tweet

Surveillance options for individuals with germline BRCA mutations are necessarily built on expert opinion. Unfortunately, there has been no formal demonstration that any approach will impact cancer-specific mortality in this population. Nonetheless, the ability to identify an at-risk population presents an opportunity to apply proactive, potentially life-saving programs for primary and secondary cancer prevention.

Such programs have been proposed by the ELSI consortium in the United States and by the French National Ad Hoc Committee in Europe. The surveillance program currently recommended at Memorial Sloan-Kettering is outlined in Table 11.4. For management of female breast cancer risk, women should be educated in the practice of monthly breast self-examination between the ages of 18 and 20.

Clinical breast examination should be performed three to four times a year, beginning at age 25. Annual mammography should also be performed beginning at age 25, although breast density may preclude satisfactory examination in the youngest women. The utility of other breast screening modalities (e.g., ultrasound, MRI) is unclear, and these procedures should currently be considered investigational. 

There are no published recommendations for screening of males at inherited risk for breast cancer. It is rational, but unproven, to suggest self-examination and periodic clinical examination by an experienced provider. The utility of screening mammography in such men is undefined.

For management of ovarian cancer risk, biannual transvaginal pelvic ultrasound should be performed beginning at age 35. Biannual measurement of serum CA-125 is also suggested. Ovarian screening can be deferred until slightly later than breast screening as few hereditary ovarian cancers occur before the age of 35.

It is reasonable to consider screening for some of the other tumor types that have been reported to be part of the spectrum of malignancies associated with BRCA mutations. In particular, screening for colon and prostate cancers should be considered, beginning at age 40.

Mark E. Robson
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 2003

References

RELATED STORIES:
Course of Women Who Develop Breast Cancer While Receiving HRT   Identifying women at high risk for breast cancer   Uterine or Ovarian Enlargement in patients with breast cancer   Menopausal Health After Breast Cancer   Mammography and Beyond: Executive Summary   Axillary Surgery   Breast Cancer Differential Diagnosis   Breast Cancer Treatment - Surgery   Special Clinical Forms of Breast Cancer   Radiation Therapy for Axillary Control   Ethnic Status and Mutation Prevalence - Hereditary Breast Cancer   Complications of Axillary Dissection   Rare Benign Disorders of the Breast   Quality Assurance   Functions of BRCA1 and BRCA2 and the Mechanism of Hereditary Susceptibility   Assessment of new technologies   Diagnostic Mammography   Breast Cancer Palliative Treatment   Fibroadenoma of the Breast   Breast cancer and the postmenopausal woman   Angiogenesis of Early Breast Lesions   Other Screening Tests

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]